Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Orna Therapeutics

Cell_Gene_Therapy

Cell and Gene Therapy Video Recap—February 19, 2026

This biweekly Cell and Gene Therapy video recap covers the latest regulatory…

Cell and Gene Therapy News

Cell and Gene Therapy Video Recap—February 19, 2026

This biweekly Cell and Gene Therapy video recap covers the latest regulatory…

Immunology

Immunology Today—December 10, 2025

This week’s Immunology update highlights key advances in gene therapy,…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Hematology Today—March 23, 2026
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive results in EGFR Exon20ins NSCLC
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation
Public Health Today—March 20, 2026

Tags

Andelyn Biosciences ATA-200 Bipolar Mania BlueRock Butantan-DV CABG CAP-1002 Cholestatic Pruritus Chronic disease mortality conduction-system pacing cost reduction DIPS Arena Enzalutamide FDA Digital Health Advisory FG001 fragmentomics GLP-1 Receptor Agonists gout flares HLA-restricted Jaypirca Johnson & Johnson MedTech JUST-AAV licensing live biotherapeutic product Metsera MicroRNAs Molgramostim Inhalation Solution naxtarubicin OCALIVA oncology diligence PPMS preclinical Rinvoq Rituximab Sensitive Skin Research Siam Bioscience Singapore Ministry Of Health Spikevax Stanford Medicine Sutra Medical TG Therapeutics Tisotumab Vedotin Transgene United Therapeutics Ver-A-T1D

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Hematology Today—March 23, 2026
Lucid Diligence Brief: Dizal announces Zegfrovy (sunvozertinib) positive results in EGFR Exon20ins NSCLC
Lucid Diligence Brief: Fauna Bio obesity target designation with Lilly
Lucid Diligence Brief: Novartis to acquire Pikavation Therapeutics from Synnovation
Public Health Today—March 20, 2026

TAGS

Andelyn Biosciences ATA-200 Bipolar Mania BlueRock Butantan-DV CABG CAP-1002 Cholestatic Pruritus Chronic disease mortality conduction-system pacing cost reduction DIPS Arena Enzalutamide FDA Digital Health Advisory FG001 fragmentomics GLP-1 Receptor Agonists gout flares HLA-restricted Jaypirca Johnson & Johnson MedTech JUST-AAV licensing live biotherapeutic product Metsera MicroRNAs Molgramostim Inhalation Solution naxtarubicin OCALIVA oncology diligence PPMS preclinical Rinvoq Rituximab Sensitive Skin Research Siam Bioscience Singapore Ministry Of Health Spikevax Stanford Medicine Sutra Medical TG Therapeutics Tisotumab Vedotin Transgene United Therapeutics Ver-A-T1D

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy